The combination of these findings with our data showing that SARM1 activation in human neurons is reversible raises the possibility that highly specific SARM1 activators could be peripherally administered for selective and reversible neuroablation in neurological conditions characterised by dystonia, spasticity, and neuropathic pain. Here, SARM1 is linked to Dystonia.